Skip to main content
. 2022 Apr 20;14(9):2061. doi: 10.3390/cancers14092061

Figure 2.

Figure 2

The diagnostic capability of cfDNA for detecting HCC patients from non-cancer (NC) cohorts: (A) the expression profiles of serum enzymes, plasma cfDNA, and cfAFP-DNA quantified from a total of 152 HCC patients and 97 non-cancer cohorts, which include 43 patients diagnosed with liver cirrhosis (LC), 24 patients diagnosed with alcoholic liver hepatitis (LA), and 30 healthy donors (HD). (B,C) ROC curves for diagnosing HCC from NC, LC, LA, and HDs using the expression profiles of serum enzymes, plasma cfDNA, and cfAFP-DNA. (D) Diagnostic performance of serum enzymes, plasma cfDNA, and cfAFP-DNA for detecting HCC patients.